compounded glp-1 drugs Diabetes advocacy group discourages use of Why the FDA is cracking

10.1038/sj.cdd.4401373 134 Ozdemir KutbayN.Biray AvciC.Sarer YurekliB.Caliskan KurtC.ShademanB.GunduzC.et al (2020)

L., Muthiah, M

[DOI] [PMC free article] [PubMed] [Google Scholar] 7.Drucker DJ

Tackling obesity: empowering adults and children to live healthier lives

However, years later in 2016, a pharmacological analysis of this ligand demonstrated interspecies differences between the rodent and human GIP system and also led to the conclusion that the human Pro3(GIP) was a potent partial agonist with the ability to activate the human GIP receptor with a maximal efficiency (E max ) of 90% compared to human GIP (68)

Accessed February 23, 2026